These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
605 related articles for article (PubMed ID: 19347608)
1. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Morgan D; Sylvester H; Lucas FL; Miesfeldt S Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608 [TBL] [Abstract][Full Text] [Related]
2. Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study. Conley CC; Kasting ML; Augusto BM; Garcia JD; Cragun D; Gonzalez BD; Kim J; Ashing KT; Knott CL; Hughes-Halbert C; Pal T; Vadaparampil ST Ann Surg Oncol; 2020 May; 27(5):1659-1670. PubMed ID: 31677107 [TBL] [Abstract][Full Text] [Related]
3. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374 [TBL] [Abstract][Full Text] [Related]
4. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know. Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561 [TBL] [Abstract][Full Text] [Related]
6. Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers. MacDonald DJ; Sarna L; Uman GC; Grant M; Weitzel JN Oncol Nurs Forum; 2006 Nov; 33(2):E27-35. PubMed ID: 16518435 [TBL] [Abstract][Full Text] [Related]
7. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Tong A; Kelly S; Nusbaum R; Graves K; Peshkin BN; Valdimarsdottir HB; Wood M; McKinnon W; Garber J; McCormick SR; Jandorf L; Schwartz MD Psychooncology; 2015 Jan; 24(1):33-9. PubMed ID: 24839250 [TBL] [Abstract][Full Text] [Related]
8. Risk management options elected by women after testing positive for a BRCA mutation. Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485 [TBL] [Abstract][Full Text] [Related]
9. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
10. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445 [TBL] [Abstract][Full Text] [Related]
12. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations. Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390 [TBL] [Abstract][Full Text] [Related]
13. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA; Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574 [TBL] [Abstract][Full Text] [Related]
14. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209 [TBL] [Abstract][Full Text] [Related]
15. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535 [TBL] [Abstract][Full Text] [Related]
16. Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing. Mannis GN; Fehniger JE; Creasman JS; Jacoby VL; Beattie MS JAMA Intern Med; 2013 Jan; 173(2):96-103. PubMed ID: 23247828 [TBL] [Abstract][Full Text] [Related]
17. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene. Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514 [TBL] [Abstract][Full Text] [Related]
18. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Nelson HD; Pappas M; Cantor A; Haney E; Holmes R JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902 [TBL] [Abstract][Full Text] [Related]
19. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. Schrag D; Kuntz KM; Garber JE; Weeks JC JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701 [TBL] [Abstract][Full Text] [Related]
20. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Botkin JR; Smith KR; Croyle RT; Baty BJ; Wylie JE; Dutson D; Chan A; Hamann HA; Lerman C; McDonald J; Venne V; Ward JH; Lyon E Am J Med Genet A; 2003 Apr; 118A(3):201-9. PubMed ID: 12673648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]